Educational only. Not medical advice. Invite-only research preview.No PHI. Do not share patient names or identifying information (HIPAA).
MytoIntelligence
All targets

Molecular target

Cyclin-Dependent Kinases / Cell Cycle

Also: CDK4/6, Cell-Cycle Regulation · id CDK

Cyclin-dependent kinases governing cell-cycle progression; CDK4/6-inhibitor drugs (palbociclib, ribociclib, abemaciclib) arrest proliferation in hormone-receptor-positive cancers. Certain flavonoids (apigenin, luteolin, fisetin) have been investigated for cell-cycle-arrest activity in preclinical studies.

3 drugs act here1 plant reach it via their compounds

Educational use only. This page summarizes published research and traditional-use records for educational purposes. It does not diagnose, treat, cure, or prevent any disease. Do not start, stop, or change medications based on this information. Discuss any decisions about therapies — pharmaceutical or botanical — with a qualified clinician who knows your medical history.

No PHI / HIPAA notice: Do not share Protected Health Information (PHI) of any patient on this site — including names, dates of birth, addresses, MRNs, or any identifying information. Use abstract case framing only. Sharing PHI with non-covered entities risks HIPAA violation regardless of platform capability.

Pharmaceutical agents

Drugs that act on Cyclin-Dependent Kinases / Cell Cycle

These medications have Cyclin-Dependent Kinases / Cell Cycle among their molecular targets. Sharing a target is a mechanistic relationship — it does not make any plant below an alternative to, or substitute for, these drugs.

Botanical connections

Plants whose compounds act on Cyclin-Dependent Kinases / Cell Cycle

Each plant below contains a named compound documented to act on Cyclin-Dependent Kinases / Cell Cycle. The compound and the reason for the connection are shown on every edge — a shared mechanism, not a therapeutic equivalence.

  • ApigeninFlavone

    Apigenin binds GABA-A at the benzodiazepine site (its anxiolytic mechanism) and has separately been investigated for cyclin-dependent-kinase-mediated cell-cycle arrest in preclinical cancer models. Research only — not a treatment claim.

A shared molecular target shows how a botanical and a drug relate mechanistically. It is not evidence that one can replace the other. Educational summary only — discuss any medication decision with your clinician.